Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Clinical trial NCT02425306 · TERMINATED
Trial details
- NCT number
- NCT02425306
- Sponsor
- Craig L Slingluff, Jr
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-12
- Primary completion
- 2017-08-18
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.